Aass H, Hedberg A, Skomedal T, Carlsson E, Osnes J B
Acta Pharmacol Toxicol (Copenh). 1983 Jul;53(1):3-11. doi: 10.1111/j.1600-0773.1983.tb01859.x.
The partial beta-agonist prenalterol has been found to differ from the full agonist isoprenaline in some aspects of its cardiac action. We therefore studied in rat myocardium whether prenalterol elicited the same qualitative changes of the contraction-relaxation cycle as was previously found for isoprenaline. We also measured binding of prenalterol to beta-adrenoceptors. Prenalterol augmented relaxation more than contraction and thus evoked the same qualitative changes of the contraction-relaxation cycle as did isoprenaline. However, the response developed slower than that to isoprenaline, and the effect on relaxation followed a more protracted time course than the effect on contraction. Prenalterol bound non-selectively to beta 1- and beta 2-adrenoceptors in both heart and lung broken cell preparations. pKd for binding to beta-adrenoceptors and pD2 values for functional effects in heart were similar, i.e. prenalterol had to occupy half the amount of beta-adrenoceptors in order to evoke half-maximal functional effects. The non-selective alpha-blocker phentolamine potentiated the effects of prenalterol on contraction, but did not change the equilibrium binding of prenalterol to cardiac beta-adrenoceptors. Phentolamine did not change the potency and efficacy of isoprenaline. Thus, although prenalterol qualitatively evoked the same response as isoprenaline, it also exhibited some properties which differed.
已发现部分β激动剂普瑞特罗在心脏作用的某些方面与完全激动剂异丙肾上腺素有所不同。因此,我们在大鼠心肌中研究了普瑞特罗是否会引发与异丙肾上腺素先前发现的相同的收缩 - 舒张周期定性变化。我们还测量了普瑞特罗与β肾上腺素能受体的结合情况。普瑞特罗增强舒张的作用大于收缩,因此引发了与异丙肾上腺素相同的收缩 - 舒张周期定性变化。然而,其反应的发展比异丙肾上腺素慢,并且对舒张的影响比收缩的影响持续时间更长。在心脏和肺破碎细胞制剂中,普瑞特罗非选择性地与β1和β2肾上腺素能受体结合。与β肾上腺素能受体结合的pKd值和在心脏中的功能效应的pD2值相似,即普瑞特罗必须占据一半数量的β肾上腺素能受体才能引发半数最大功能效应。非选择性α阻滞剂酚妥拉明增强了普瑞特罗对收缩的作用,但未改变普瑞特罗与心脏β肾上腺素能受体的平衡结合。酚妥拉明未改变异丙肾上腺素的效价和效能。因此,尽管普瑞特罗在定性上引发了与异丙肾上腺素相同的反应,但它也表现出一些不同的特性。